111 related articles for article (PubMed ID: 11571514)
41. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
[TBL] [Abstract][Full Text] [Related]
42. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Kang HJ; Shin HY; Choi HS; Han KS; Ahn HS
Bone Marrow Transplant; 2004 Mar; 33(5):471-6. PubMed ID: 14716339
[TBL] [Abstract][Full Text] [Related]
43. [Bacteremia due to Capnocytophaga spp.: two cases].
García J; Lizasoain M; Lahuerta JJ; Sanz F
Enferm Infecc Microbiol Clin; 2003 Mar; 21(3):168-9. PubMed ID: 12586027
[No Abstract] [Full Text] [Related]
44. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
[TBL] [Abstract][Full Text] [Related]
45. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
46. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
47. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
D'Sa S; Yong K; Kyriakou C; Bhattacharya S; Peggs KS; Foulkes B; Watts MJ; Ings SJ; Ardeshna KM; Goldstone AH; Williams CD
Br J Haematol; 2004 Jun; 125(6):756-65. PubMed ID: 15180865
[TBL] [Abstract][Full Text] [Related]
48. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH
Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602
[TBL] [Abstract][Full Text] [Related]
49. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
50. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
51. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
[TBL] [Abstract][Full Text] [Related]
52. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
53. Hemolytic uremic syndrome after autologous BMT without TBI.
Raybon KB; Snyder MJ; Halvorson RD
Bone Marrow Transplant; 1996 May; 17(5):897-8. PubMed ID: 8733719
[No Abstract] [Full Text] [Related]
54. Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Rao PS
Am J Kidney Dis; 2005 Apr; 45(4):780-5. PubMed ID: 15806483
[No Abstract] [Full Text] [Related]
55. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Jones RB; Matthes S; Shpall EJ; Fisher JH; Stemmer SM; Dufton C; Stephens JK; Bearman SI
J Natl Cancer Inst; 1993 Apr; 85(8):640-7. PubMed ID: 8468721
[TBL] [Abstract][Full Text] [Related]
56. delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients.
Gonçalves TL; Benvegnú DM; Bonfanti G; Frediani AV; Rocha JB
Pharmacol Res; 2009 Apr; 59(4):279-84. PubMed ID: 19162187
[TBL] [Abstract][Full Text] [Related]
57. Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
Broun GO; Petruska PJ; Hiramoto RN; Cohen HJ
Cancer Treat Rep; 1982 Feb; 66(2):237-42. PubMed ID: 7034931
[TBL] [Abstract][Full Text] [Related]
58. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
Chap L; Shpiner R; Levine M; Norton L; Lill M; Glaspy J
Bone Marrow Transplant; 1997 Dec; 20(12):1063-7. PubMed ID: 9466279
[TBL] [Abstract][Full Text] [Related]
59. Fatal cardiac toxicity in two patients receiving same-day administration of cyclophosphamide and cytarabine as conditioning for hematopoietic stem cell transplantation.
Kanda Y; Matsumura T; Maki K; Matsuyama T; Chiba S; Hirai H
Haematologica; 2001 Sep; 86(9):1002-3. PubMed ID: 11532636
[No Abstract] [Full Text] [Related]
60. [Severe esophageal stenosis secondary to the administration of chemotherapy in a patient with acute myeloblastic leukemia].
Canales Albendea MA; Alvarez Román MT; Villanueva Pavón R; Hernández Navarro F
Sangre (Barc); 1999 Jun; 44(3):245-6. PubMed ID: 10481595
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
